Effect of simvastatin plus cetuximab/irinotecan for KRAS mutant colorectal cancer and predictive value of the RAS signature for treatment response to cetuximab - Lee, J; Hong, Y S; Hong, J Y (Invest New Drugs, 2014)
et al.